Cancer

DNA Test
Health

What’s a polygenic risk score and how good is it at predicting disease?

By Rebecca Robbins, Damian Garde, and Adam Feuerstein

STAT SPOTLIGHT
Biotech

Startup Spotlight: PanTher’s drug-delivery patch aims to knock down the ‘wall’ of pancreatic cancer

By Kate Sheridan

NIH headquarters
Exclusive

Freeze on fetal tissue procurement may impede work at NIH cancer lab, agency says

By Ike Swetlitz

Robotic prostatectomy
Health

Long-term study shows most prostate cancer patients don’t need aggressive treatment

By Karen Weintraub

Cambridgeport
Exclusive

New documents shed light on secretive ElevateBio, next step for former Alexion execs

By Kate Sheridan

Memorial Sloan Kettering
Hospitals

Top cancer center’s business deals created a web of conflicts, say ethics experts

By Casey Ross and Ike Swetlitz

Foundation Medicine
Biotech

For one cancer patient, biotech’s genetic test turns out to be a ‘lifesaver’

By Jonathan Saltzman — Boston Globe

Glaxo Smith Kline
Pharmalot

What does Glaxo get with its Tesaro deal? Here’s what the wags are saying

By Ed Silverman

Ovarian Tumor
Biotech

GSK buys cancer biotech Tesaro for $5.1B

By Adam Feuerstein

Biotech

Unbowed by critics, Gilead’s cancer chief pushes ahead with growth plans

By Adam Feuerstein

Adam's Take

Misfortune strikes a Bluebird patient, highlighting the safety risks involved with gene therapy

By Adam Feuerstein

Adam's Take

Ziopharm shares are moving higher on a turnaround strategy, but is it for real? A closer look

By Adam Feuerstein

Radiation and Isotopes Centre Khartoum
First Opinion

Patients of African descent are being denied the benefits of cancer breakthroughs. We’re changing that

By Jennifer Dent

SQZ Biotech GIF
Biotech

SQZ Biotech pushes forward with its method to squeeze drugs into cells

By Kate Sheridan

Legend Biotech lab
Biotech

A Chinese CAR-T company got the world’s attention with early data. At ASH, it has questions to answer

By Rebecca Robbins

Nick Leschly - Bluebird Bio
Health

As new therapies arrive, pressure builds on the health care system to figure out how to pay for them

By Andrew Joseph

Medication production
Pharmalot

A big Indian generics maker failed an FDA inspection, but how bad was it?

By Ed Silverman

Brigham - Dr. Elizabeth Nabel
Hospitals

Covering the cost of high-priced therapies like CAR-T is ‘not sustainable,’ hospital chief says

By Andrew Joseph

Fecal Transplants FDA
Health

Patients on checkpoint inhibitors sometimes develop severe colitis. Could fecal transplants help?

By Megan Thielking

Driver app
Exclusive

‘We ran out of money’: High-profile startup seeking to connect patients with clinical trials shuts down

By Rebecca Robbins

The Readout LOUD

LISTEN: What the midterms mean, a golden age on hold, and the $4 million drug

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Metastatic Melanoma Cells
Adam's Take

Skin cancer immunotherapy could have potential but don’t hang hopes on new data

By Adam Feuerstein

The Readout LOUD

LISTEN: Biotech’s October surprise, the precise cost of precision, and breaking postpartum silence

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Kristen Kilmer
Health

Pricey precision medicine often financially toxic for cancer patients

By Liz Szabo — Kaiser Health News

Exclusive

How an IBM Watson Health rescue mission collapsed — and a top executive was ousted

By Casey Ross and Ike Swetlitz

Cervical Cancer Surgery Surprise
Health

More deaths seen for less invasive cervical cancer surgery

By Associated Press

Pharmalot

J&J loses patent fight over key prostate cancer drug, teeing up generic competition

By Ed Silverman

Sputnik
First Opinion

The West is losing the gene editing race. It needs to catch up

By André Choulika

Vasant "Vas" Narasimhan
Business

Novartis CEO Vas Narasimhan on gene therapy, innovation, and the company pivot

By Karen Weintraub

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy